For example, a patient with type 2 diabetes on GLP-1 scheduled for hip replacement may continue the agent until 1 to 2 weeks pre-op if weight loss is modest, but stop earlier if gastroparesis or severe nausea is present
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B
Rising Adverse Events The FDA recently reported receiving serious adverse events linked to 'compounded semaglutide.' The specifics are yet to be disclosed but are expected to be released soon
Fast, Affordable Telehealth Options with Doctronic.AI Many people want quick answers before booking an in-person visit
And that, after all, is the entire point of the work we all do